ResultsBusinessLine
Alkem PAT down at ₹675 crore; biotech sales down 37%
GreyOak summary
Alkem Laboratories reported a 12% drop in consolidated net profit to ₹675 crore for Q2 ended September 30, 2026. While total revenue grew 13.8% to ₹4,552 crore, biotech sales declined 35% due to the lumpy nature of the CDMO business. India sales grew 9.5% to ₹3,027 crore, accounting for over 60% of revenue, while international sales rose 22.3%.
What it affects
- Alkem LaboratoriesALKEMNegative -67
PAT down 12% to ₹675 croreRolling sentiment Negative -57
Source
Read the original at BusinessLineMore Alkem Laboratories news
- Alkem Lab Q2 profit falls 14.4% to Rs 667 crBusiness Standard · Results ·
- Alkem Labs Q2 revenue rises 14%, profit fallsCNBC-TV18 · Results ·
- Alkem Q2 Net Profit Falls 12% To Rs 675 CrNDTV Profit · Results ·
- Five Stocks To Buy Today, November 9: Alkem Labs, MTNL, Wockhardt And MoreNDTV Profit · Stock view ·
- GIFT Nifty up 66 points; Adani, BHEL, Alkem, Dabur in focusBusiness Today · Market wrap ·